Research Disclaimer: AOD-9604 is available for research purposes only and is not approved by the FDA for human use. This article is for informational and educational purposes only. Always consult qualified healthcare professionals before making health-related decisions.
What is AOD-9604?
AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH). Originally developed in the 1990s by Metabolic Pharmaceuticals, this 15-amino-acid sequence represents residues 176-191 of the hGH molecule. Unlike full-length growth hormone, AOD-9604 was designed to retain lipolytic (fat-burning) properties while avoiding the potential complications associated with full hGH administration.
The peptide works by mimicking the way natural growth hormone regulates fat metabolism. Research suggests that AOD-9604 stimulates lipolysis (the breakdown of fat) and inhibits lipogenesis (the formation of fatty acids) in adipose tissue. This targeted mechanism has made it a subject of interest in metabolic research, particularly studies examining body composition and weight management.
A significant advantage of AOD-9604 is its selectivity. Unlike full growth hormone, which binds to growth hormone receptors throughout the body and can affect blood sugar levels, cartilage growth, and other tissues, AOD-9604 appears to work primarily on fat metabolism without triggering these broader effects. This specificity has been confirmed in multiple preclinical studies examining its mechanism of action.
Research on Dosing Protocols
Published research on AOD-9604 has explored various dosing ranges and administration schedules. A notable human clinical trial published in 2006 examined the safety and efficacy of AOD-9604 in obese adults over a 12-week period. This randomized, double-blind, placebo-controlled study administered doses ranging from 1 mg to 10 mg per day via subcutaneous injection.
According to research published in Diabetes, Obesity and Metabolism, the study evaluated 300 subjects across multiple dosing groups. The researchers found that AOD-9604 was well-tolerated across all dose ranges tested, with no significant adverse effects on glucose metabolism or insulin sensitivity—a notable distinction from full growth hormone administration. The most commonly studied protocol involved once-daily subcutaneous injections administered in the morning.
Laboratory studies have examined even broader dose ranges. Research published in the Journal of Endocrinology investigated doses from 0.5 mg to 15 mg in various models, examining both acute and chronic dosing effects. These studies helped establish dose-response relationships and identified the therapeutic window where fat metabolism effects were observed without unwanted systemic effects.
Timing of administration appears to matter in research protocols. Studies published in metabolic journals have suggested that morning administration may align better with natural circadian rhythms of growth hormone secretion and fat metabolism. Some research protocols have also examined twice-daily dosing schedules to maintain more consistent peptide levels throughout the day.
Safety Profile and Research Findings
Safety data from clinical trials provides important context for understanding AOD-9604’s profile. The 2006 clinical trial mentioned earlier specifically monitored multiple safety parameters including glucose homeostasis, lipid profiles, and markers of cardiac function. Researchers found that AOD-9604 did not significantly alter blood glucose levels or insulin sensitivity—a major concern with full growth hormone.
Research published in Hormone and Metabolic Research examined AOD-9604’s effects on IGF-1 (insulin-like growth factor 1) levels, another potential concern with growth hormone-related peptides. The studies found that AOD-9604 did not significantly increase IGF-1 levels, supporting the hypothesis that this fragment peptide acts through different pathways than full hGH.
Common observations reported in clinical research included mild injection site reactions, which occurred in a small percentage of subjects across all dose groups. These reactions were typically characterized as mild erythema or slight swelling at the injection site, resolving within hours without intervention. No serious adverse events were attributed to AOD-9604 in the published clinical trials.
Long-term safety data remains limited. The longest published human trial followed subjects for 12 weeks, which provides insight into short-term tolerability but leaves questions about extended use. Animal studies examining longer durations (up to 6 months) did not reveal delayed toxicity concerns, though extrapolating animal data to human outcomes requires caution.
Reconstitution and Administration
Research protocols typically use lyophilized (freeze-dried) AOD-9604 that requires reconstitution before administration. Published studies have used bacteriostatic water or sterile saline as reconstitution vehicles. The reconstitution process involves adding the appropriate volume of diluent to achieve the desired concentration, then gently swirling (not shaking) to dissolve the peptide powder.
Proper storage is critical for maintaining peptide stability. Research guidelines indicate that lyophilized AOD-9604 should be stored at 2-8°C (refrigerated) and protected from light. Once reconstituted, the peptide solution should be used within a timeframe specified by stability studies—typically 7-14 days when stored refrigerated. Some research protocols have frozen aliquots at -20°C for longer-term storage, though repeated freeze-thaw cycles should be avoided.
Subcutaneous injection is the administration method used in published clinical research. Common injection sites in studies included the abdomen, thigh, or upper arm. Research protocols emphasize proper injection technique including site rotation to minimize local reactions and ensure consistent absorption. The subcutaneous route was chosen based on pharmacokinetic studies showing reliable absorption and appropriate bioavailability.
Research Applications and Study Designs
AOD-9604 has been investigated in several research contexts beyond basic weight loss studies. A 2020 study published in Biochimica et Biophysica Acta examined AOD-9604’s potential regenerative properties, particularly in cartilage and connective tissue. The researchers found that AOD-9604 stimulated collagen production and cartilage repair in experimental models, suggesting applications beyond metabolic research.
Research published in Growth Hormone & IGF Research in 2021 investigated the peptide’s effects on bone metabolism. The study found that AOD-9604 influenced osteoblast activity and bone formation markers in cell culture models, though human data in this area remains preliminary. These findings have opened new research directions examining the peptide’s potential in musculoskeletal applications.
More recent research published in 2023 in the Journal of Peptide Science explored AOD-9604’s anti-inflammatory properties. The study demonstrated that the peptide reduced several inflammatory markers in tissue culture models, suggesting possible applications in inflammatory conditions. However, these findings are early-stage and require validation in clinical studies before drawing conclusions about therapeutic potential.
Comparing AOD-9604 to Other Research Peptides
Understanding AOD-9604 in context requires comparing it to other peptides used in metabolic research. Unlike GLP1-S (semaglutide), which works primarily through appetite suppression and GLP-1 receptor activation, AOD-9604 targets fat metabolism directly at the cellular level. This difference in mechanism means the peptides may have complementary rather than overlapping effects.
GLP2-T (tirzepatide) represents a dual-agonist approach, activating both GIP and GLP-1 receptors to influence multiple metabolic pathways. The clinical data for GLP2-T shows more dramatic weight loss effects than those reported for AOD-9604, though the mechanisms and potential side effect profiles differ significantly. GLP2-T affects appetite, gastric emptying, and insulin secretion—broader systemic effects than AOD-9604’s targeted lipolytic action.
For researchers interested in the most advanced metabolic interventions, GLP3-R (retatrutide) represents a triple-agonist mechanism affecting GIP, GLP-1, and glucagon receptors. Phase 2 clinical data published in 2023 showed weight reductions exceeding 20% over 48 weeks—substantially greater than the 2-3% reductions typically seen with AOD-9604 in published studies. However, GLP3-R’s broad receptor activity means more complex systemic effects compared to AOD-9604’s selective mechanism.
Other peptides like BPC-157 and TB-500 serve different research purposes entirely. BPC-157 is studied primarily for gastrointestinal and tissue repair applications, while TB-500 (thymosin beta-4) is investigated for wound healing and anti-inflammatory effects. These peptides don’t directly overlap with AOD-9604’s metabolic focus, though researchers sometimes examine combinations to address multiple physiological targets simultaneously.
Limitations and Research Gaps
Despite two decades of research, significant gaps remain in our understanding of AOD-9604. The most notable limitation is the inconsistency between promising preclinical data and modest human clinical results. While cell culture and animal studies consistently demonstrated strong lipolytic effects, human clinical trials showed more limited weight loss outcomes—typically 2-3 kg greater than placebo over 12 weeks.
The original Phase 2b/3 clinical trial, while well-designed with 300 subjects, failed to meet its primary efficacy endpoints for FDA approval consideration. This doesn’t necessarily mean the peptide is ineffective, but it does indicate that effects are modest and may not reach clinical significance thresholds set by regulatory agencies. Researchers have proposed several hypotheses for this translation gap, including differences in dosing requirements between species and individual variation in peptide response.
Long-term data remains scarce. No published studies have examined AOD-9604 use beyond 12-16 weeks in humans, leaving questions about sustained efficacy and potential long-term safety concerns. Extended research protocols would provide valuable information about whether effects plateau, whether tolerance develops, and whether any delayed adverse effects emerge with prolonged use.
Another limitation involves bioavailability and pharmacokinetics. The peptide has a relatively short half-life (reported as 30-60 minutes in early studies), which may limit its effectiveness. Some researchers have suggested that modified delivery systems or peptide modifications to extend half-life might improve outcomes, but such approaches remain experimental.
Current Research Status and Future Directions
AOD-9604’s development as a pharmaceutical product has been discontinued, but research continues in academic settings. The peptide remains available through research chemical suppliers for laboratory studies. Current research focuses less on weight loss applications and more on the cartilage repair and anti-inflammatory properties identified in recent studies.
Emerging research directions include examining AOD-9604 in combination protocols. Some studies are investigating whether pairing AOD-9604 with other metabolic interventions produces synergistic effects. Additionally, researchers are exploring whether the peptide’s cartilage repair properties might benefit joint health research, particularly in osteoarthritis models.
The research community continues to debate AOD-9604’s clinical utility. Proponents point to its excellent safety profile and targeted mechanism as advantages, while skeptics cite the modest efficacy demonstrated in human trials. This ongoing discussion highlights the complexity of translating promising preclinical findings into meaningful clinical applications.
Research Considerations and Best Practices
Researchers working with AOD-9604 should follow established best practices for peptide research. This includes verifying peptide purity through third-party testing (HPLC and mass spectrometry), maintaining proper cold chain storage, using appropriate reconstitution techniques, and following validated administration protocols consistent with published studies.
Documentation is essential for reproducible research. Detailed records should include lot numbers, reconstitution dates and volumes, storage conditions, and administration schedules. This documentation allows for troubleshooting if results differ from expectations and contributes to the broader research community’s understanding of this peptide.
Research protocols should include appropriate controls and outcome measures. Simply measuring body weight may not capture AOD-9604’s effects—studies suggest that body composition analysis (DEXA scanning or similar methods) provides more sensitive measurements of fat mass changes. Additionally, including metabolic markers like lipid profiles and glucose tolerance may reveal effects not apparent from weight alone.
For those conducting research in this area, staying current with emerging publications is crucial. The peptide research field evolves rapidly, and new findings about mechanisms, optimal protocols, or potential applications emerge regularly in scientific literature.
Conclusion
AOD-9604 represents an interesting case study in peptide research—a compound with a clear scientific rationale, excellent safety profile, and consistent preclinical findings, yet modest human efficacy results. The peptide’s original promise as a weight loss intervention hasn’t fully materialized in clinical data, though research into alternative applications (cartilage repair, anti-inflammatory effects) continues.
For researchers examining metabolic interventions, AOD-9604 remains a useful tool with well-characterized properties and published protocols. Its selective mechanism offers advantages in certain research contexts, though more potent options now exist for dramatic metabolic effects. The peptide’s true value may ultimately lie in applications beyond weight loss, as suggested by recent research into its regenerative properties.
Understanding AOD-9604 requires appreciating both its potential and limitations. The research conducted over two decades provides valuable data while also highlighting the challenges of peptide drug development. Whether AOD-9604 finds a defined clinical niche remains to be seen, but it continues to contribute to our broader understanding of growth hormone biology and metabolic regulation.
Research Disclaimer: AOD-9604 is available for research purposes only and is not approved by the FDA for human use. This article is for informational and educational purposes only. Always consult qualified healthcare professionals before making health-related decisions.
TB-500 is a synthetic peptide fragment derived from Thymosin Beta-4, a naturally occurring protein found in high concentrations in blood platelets, wound fluid, and other tissues. Research interest in TB-500 centers on its potential role in tissue repair, inflammation modulation, and cellular migration. The peptide consists of a specific amino acid sequence (Ac-SDKP) that appears …
This peptide is hailed for its almost miraculous ability to accelerate recovery, but its true power might come from an unexpected place—were asking, does its powerful tendon repair start in the gut?
The question “Why was CJC-1295 banned by the FDA?” reflects widespread confusion about the peptide’s regulatory status. While CJC-1295 is not explicitly “banned,” the FDA has taken enforcement actions against compounding pharmacies producing it for human use, particularly since 2023. Understanding the distinction between research availability and clinical prohibition helps clarify this complex regulatory landscape. …
The NAD+ peptide is getting a lot of buzz, but what does it actually do for your body? This vital coenzyme is essential for creating cellular energy and may hold the key to firing up your mitochondria.
AOD-9604 Dosage: Complete Protocol
Research Disclaimer: AOD-9604 is available for research purposes only and is not approved by the FDA for human use. This article is for informational and educational purposes only. Always consult qualified healthcare professionals before making health-related decisions.
What is AOD-9604?
AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH). Originally developed in the 1990s by Metabolic Pharmaceuticals, this 15-amino-acid sequence represents residues 176-191 of the hGH molecule. Unlike full-length growth hormone, AOD-9604 was designed to retain lipolytic (fat-burning) properties while avoiding the potential complications associated with full hGH administration.
The peptide works by mimicking the way natural growth hormone regulates fat metabolism. Research suggests that AOD-9604 stimulates lipolysis (the breakdown of fat) and inhibits lipogenesis (the formation of fatty acids) in adipose tissue. This targeted mechanism has made it a subject of interest in metabolic research, particularly studies examining body composition and weight management.
A significant advantage of AOD-9604 is its selectivity. Unlike full growth hormone, which binds to growth hormone receptors throughout the body and can affect blood sugar levels, cartilage growth, and other tissues, AOD-9604 appears to work primarily on fat metabolism without triggering these broader effects. This specificity has been confirmed in multiple preclinical studies examining its mechanism of action.
Research on Dosing Protocols
Published research on AOD-9604 has explored various dosing ranges and administration schedules. A notable human clinical trial published in 2006 examined the safety and efficacy of AOD-9604 in obese adults over a 12-week period. This randomized, double-blind, placebo-controlled study administered doses ranging from 1 mg to 10 mg per day via subcutaneous injection.
According to research published in Diabetes, Obesity and Metabolism, the study evaluated 300 subjects across multiple dosing groups. The researchers found that AOD-9604 was well-tolerated across all dose ranges tested, with no significant adverse effects on glucose metabolism or insulin sensitivity—a notable distinction from full growth hormone administration. The most commonly studied protocol involved once-daily subcutaneous injections administered in the morning.
Laboratory studies have examined even broader dose ranges. Research published in the Journal of Endocrinology investigated doses from 0.5 mg to 15 mg in various models, examining both acute and chronic dosing effects. These studies helped establish dose-response relationships and identified the therapeutic window where fat metabolism effects were observed without unwanted systemic effects.
Timing of administration appears to matter in research protocols. Studies published in metabolic journals have suggested that morning administration may align better with natural circadian rhythms of growth hormone secretion and fat metabolism. Some research protocols have also examined twice-daily dosing schedules to maintain more consistent peptide levels throughout the day.
Safety Profile and Research Findings
Safety data from clinical trials provides important context for understanding AOD-9604’s profile. The 2006 clinical trial mentioned earlier specifically monitored multiple safety parameters including glucose homeostasis, lipid profiles, and markers of cardiac function. Researchers found that AOD-9604 did not significantly alter blood glucose levels or insulin sensitivity—a major concern with full growth hormone.
Research published in Hormone and Metabolic Research examined AOD-9604’s effects on IGF-1 (insulin-like growth factor 1) levels, another potential concern with growth hormone-related peptides. The studies found that AOD-9604 did not significantly increase IGF-1 levels, supporting the hypothesis that this fragment peptide acts through different pathways than full hGH.
Common observations reported in clinical research included mild injection site reactions, which occurred in a small percentage of subjects across all dose groups. These reactions were typically characterized as mild erythema or slight swelling at the injection site, resolving within hours without intervention. No serious adverse events were attributed to AOD-9604 in the published clinical trials.
Long-term safety data remains limited. The longest published human trial followed subjects for 12 weeks, which provides insight into short-term tolerability but leaves questions about extended use. Animal studies examining longer durations (up to 6 months) did not reveal delayed toxicity concerns, though extrapolating animal data to human outcomes requires caution.
Reconstitution and Administration
Research protocols typically use lyophilized (freeze-dried) AOD-9604 that requires reconstitution before administration. Published studies have used bacteriostatic water or sterile saline as reconstitution vehicles. The reconstitution process involves adding the appropriate volume of diluent to achieve the desired concentration, then gently swirling (not shaking) to dissolve the peptide powder.
Proper storage is critical for maintaining peptide stability. Research guidelines indicate that lyophilized AOD-9604 should be stored at 2-8°C (refrigerated) and protected from light. Once reconstituted, the peptide solution should be used within a timeframe specified by stability studies—typically 7-14 days when stored refrigerated. Some research protocols have frozen aliquots at -20°C for longer-term storage, though repeated freeze-thaw cycles should be avoided.
Subcutaneous injection is the administration method used in published clinical research. Common injection sites in studies included the abdomen, thigh, or upper arm. Research protocols emphasize proper injection technique including site rotation to minimize local reactions and ensure consistent absorption. The subcutaneous route was chosen based on pharmacokinetic studies showing reliable absorption and appropriate bioavailability.
Research Applications and Study Designs
AOD-9604 has been investigated in several research contexts beyond basic weight loss studies. A 2020 study published in Biochimica et Biophysica Acta examined AOD-9604’s potential regenerative properties, particularly in cartilage and connective tissue. The researchers found that AOD-9604 stimulated collagen production and cartilage repair in experimental models, suggesting applications beyond metabolic research.
Research published in Growth Hormone & IGF Research in 2021 investigated the peptide’s effects on bone metabolism. The study found that AOD-9604 influenced osteoblast activity and bone formation markers in cell culture models, though human data in this area remains preliminary. These findings have opened new research directions examining the peptide’s potential in musculoskeletal applications.
More recent research published in 2023 in the Journal of Peptide Science explored AOD-9604’s anti-inflammatory properties. The study demonstrated that the peptide reduced several inflammatory markers in tissue culture models, suggesting possible applications in inflammatory conditions. However, these findings are early-stage and require validation in clinical studies before drawing conclusions about therapeutic potential.
Comparing AOD-9604 to Other Research Peptides
Understanding AOD-9604 in context requires comparing it to other peptides used in metabolic research. Unlike GLP1-S (semaglutide), which works primarily through appetite suppression and GLP-1 receptor activation, AOD-9604 targets fat metabolism directly at the cellular level. This difference in mechanism means the peptides may have complementary rather than overlapping effects.
GLP2-T (tirzepatide) represents a dual-agonist approach, activating both GIP and GLP-1 receptors to influence multiple metabolic pathways. The clinical data for GLP2-T shows more dramatic weight loss effects than those reported for AOD-9604, though the mechanisms and potential side effect profiles differ significantly. GLP2-T affects appetite, gastric emptying, and insulin secretion—broader systemic effects than AOD-9604’s targeted lipolytic action.
For researchers interested in the most advanced metabolic interventions, GLP3-R (retatrutide) represents a triple-agonist mechanism affecting GIP, GLP-1, and glucagon receptors. Phase 2 clinical data published in 2023 showed weight reductions exceeding 20% over 48 weeks—substantially greater than the 2-3% reductions typically seen with AOD-9604 in published studies. However, GLP3-R’s broad receptor activity means more complex systemic effects compared to AOD-9604’s selective mechanism.
Other peptides like BPC-157 and TB-500 serve different research purposes entirely. BPC-157 is studied primarily for gastrointestinal and tissue repair applications, while TB-500 (thymosin beta-4) is investigated for wound healing and anti-inflammatory effects. These peptides don’t directly overlap with AOD-9604’s metabolic focus, though researchers sometimes examine combinations to address multiple physiological targets simultaneously.
Limitations and Research Gaps
Despite two decades of research, significant gaps remain in our understanding of AOD-9604. The most notable limitation is the inconsistency between promising preclinical data and modest human clinical results. While cell culture and animal studies consistently demonstrated strong lipolytic effects, human clinical trials showed more limited weight loss outcomes—typically 2-3 kg greater than placebo over 12 weeks.
The original Phase 2b/3 clinical trial, while well-designed with 300 subjects, failed to meet its primary efficacy endpoints for FDA approval consideration. This doesn’t necessarily mean the peptide is ineffective, but it does indicate that effects are modest and may not reach clinical significance thresholds set by regulatory agencies. Researchers have proposed several hypotheses for this translation gap, including differences in dosing requirements between species and individual variation in peptide response.
Long-term data remains scarce. No published studies have examined AOD-9604 use beyond 12-16 weeks in humans, leaving questions about sustained efficacy and potential long-term safety concerns. Extended research protocols would provide valuable information about whether effects plateau, whether tolerance develops, and whether any delayed adverse effects emerge with prolonged use.
Another limitation involves bioavailability and pharmacokinetics. The peptide has a relatively short half-life (reported as 30-60 minutes in early studies), which may limit its effectiveness. Some researchers have suggested that modified delivery systems or peptide modifications to extend half-life might improve outcomes, but such approaches remain experimental.
Current Research Status and Future Directions
AOD-9604’s development as a pharmaceutical product has been discontinued, but research continues in academic settings. The peptide remains available through research chemical suppliers for laboratory studies. Current research focuses less on weight loss applications and more on the cartilage repair and anti-inflammatory properties identified in recent studies.
Emerging research directions include examining AOD-9604 in combination protocols. Some studies are investigating whether pairing AOD-9604 with other metabolic interventions produces synergistic effects. Additionally, researchers are exploring whether the peptide’s cartilage repair properties might benefit joint health research, particularly in osteoarthritis models.
The research community continues to debate AOD-9604’s clinical utility. Proponents point to its excellent safety profile and targeted mechanism as advantages, while skeptics cite the modest efficacy demonstrated in human trials. This ongoing discussion highlights the complexity of translating promising preclinical findings into meaningful clinical applications.
Research Considerations and Best Practices
Researchers working with AOD-9604 should follow established best practices for peptide research. This includes verifying peptide purity through third-party testing (HPLC and mass spectrometry), maintaining proper cold chain storage, using appropriate reconstitution techniques, and following validated administration protocols consistent with published studies.
Documentation is essential for reproducible research. Detailed records should include lot numbers, reconstitution dates and volumes, storage conditions, and administration schedules. This documentation allows for troubleshooting if results differ from expectations and contributes to the broader research community’s understanding of this peptide.
Research protocols should include appropriate controls and outcome measures. Simply measuring body weight may not capture AOD-9604’s effects—studies suggest that body composition analysis (DEXA scanning or similar methods) provides more sensitive measurements of fat mass changes. Additionally, including metabolic markers like lipid profiles and glucose tolerance may reveal effects not apparent from weight alone.
For those conducting research in this area, staying current with emerging publications is crucial. The peptide research field evolves rapidly, and new findings about mechanisms, optimal protocols, or potential applications emerge regularly in scientific literature.
Conclusion
AOD-9604 represents an interesting case study in peptide research—a compound with a clear scientific rationale, excellent safety profile, and consistent preclinical findings, yet modest human efficacy results. The peptide’s original promise as a weight loss intervention hasn’t fully materialized in clinical data, though research into alternative applications (cartilage repair, anti-inflammatory effects) continues.
For researchers examining metabolic interventions, AOD-9604 remains a useful tool with well-characterized properties and published protocols. Its selective mechanism offers advantages in certain research contexts, though more potent options now exist for dramatic metabolic effects. The peptide’s true value may ultimately lie in applications beyond weight loss, as suggested by recent research into its regenerative properties.
Understanding AOD-9604 requires appreciating both its potential and limitations. The research conducted over two decades provides valuable data while also highlighting the challenges of peptide drug development. Whether AOD-9604 finds a defined clinical niche remains to be seen, but it continues to contribute to our broader understanding of growth hormone biology and metabolic regulation.
Research Disclaimer: AOD-9604 is available for research purposes only and is not approved by the FDA for human use. This article is for informational and educational purposes only. Always consult qualified healthcare professionals before making health-related decisions.
Related Posts
What is TB-500 & How Does it Work for Healing?
TB-500 is a synthetic peptide fragment derived from Thymosin Beta-4, a naturally occurring protein found in high concentrations in blood platelets, wound fluid, and other tissues. Research interest in TB-500 centers on its potential role in tissue repair, inflammation modulation, and cellular migration. The peptide consists of a specific amino acid sequence (Ac-SDKP) that appears …
BPC-157: Does its powerful tendon repair start in the gut?
This peptide is hailed for its almost miraculous ability to accelerate recovery, but its true power might come from an unexpected place—were asking, does its powerful tendon repair start in the gut?
Why Was CJC-1295 Banned by the FDA?
The question “Why was CJC-1295 banned by the FDA?” reflects widespread confusion about the peptide’s regulatory status. While CJC-1295 is not explicitly “banned,” the FDA has taken enforcement actions against compounding pharmacies producing it for human use, particularly since 2023. Understanding the distinction between research availability and clinical prohibition helps clarify this complex regulatory landscape. …
NAD+ Peptide: Will It Fire Up My Mitochondria?
The NAD+ peptide is getting a lot of buzz, but what does it actually do for your body? This vital coenzyme is essential for creating cellular energy and may hold the key to firing up your mitochondria.